Discover
CADL
Candel Therapeutics, Inc.
9.88
2 x 7.75
2 x 12.92
bid
ask
-
0.42
4.08%
2 @ 04:27 AM
9.83 -0.05 (0.51%)
| Ytd | 74.87% | |
| 1y | 103.71% |
9.86
day range
10.87
4.35
52 week range
11.36
| Open | 10.27 | Prev Close | 10.30 | Low | 9.86 | High | 10.87 | Mkt Cap | 723.91M |
| Vol | 1.87M | Avg Vol | 2.08M | EPS | -1.01 | P/E | N/A | Forward P/E | -9.48 |
| Beta | -0.87 | Short Ratio | 7.72 | Inst. Own | 22.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 8.20 | 200-d Avg | 6.08 | 1yr Est | 19.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | 0 | -0.33 | N/A | N/A |
| 2024-08-13 | 2024-06 | 0 | N/A | N/A | N/A |
| 2024-08-13 | 2024-06 | 0 | -0.74 | N/A | N/A |
| 2024-05-14 | 2024-03 | 0 | N/A | N/A | N/A |
| 2024-05-14 | 2024-03 | 0 | -0.28 | N/A | N/A |
| 2024-03-28 | 2023-12 | -0.16 | -0.38 | -0.22 | -137.50% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-18 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-18 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2023-11-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2023-05-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2023-05-15 | BMO Capital | Upgrade | Outperform | Outperform |
| 2023-03-31 | Credit Suisse | Upgrade | Outperform |
Profile
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-10-14 | AGUILAR-CORDOVA ESTUARDO | Beneficial Owner of more than 10% of a Class of Security | 6.05M | Sale |
| 2023-11-23 | AMELLO JASON A | Chief Financial Officer | 222.16K | Stock Award(Grant) |
| 2024-11-28 | BARONE FRANCESCA | Officer | 137.88K | Sale |
| 2024-12-15 | MANNING PAUL B. | Director | 0.00 | Purchase |
| 2024-11-28 | NICHOLS WILLIAMS GARRETT | Officer | 100.55K | Sale |
| 2024-07-16 | SCHOCH CHARLES | Chief Financial Officer | 62.52K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Northpond Ventures, Llc | 1.94M | 16.70M | 5.96% |
| 2024-09-29 | Blackrock Inc. | 1.13M | 9.71M | 3.47% |
| 2024-09-29 | Vanguard Group Inc | 946.27K | 8.17M | 2.91% |
| 2024-09-29 | State Street Corporation | 492.01K | 4.25M | 1.52% |
| 2024-09-29 | Geode Capital Management, LLC | 449.00K | 3.87M | 1.38% |
| 2024-09-29 | Sands Capital Ventures, LLC | 405.84K | 3.50M | 1.25% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | iShares Russell 2000 ETF | 511.78K | 4.42M | 1.58% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 453.81K | 3.92M | 1.40% |
| 2024-07-30 | TIAA-CREF Funds-Equity Index Fund | 265.49K | 2.29M | 0.82% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 220.07K | 1.90M | 0.68% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 203.68K | 1.76M | 0.63% |
| 2024-10-30 | iShares Russell 2000 Growth ETF | 178.36K | 1.54M | 0.55% |